title: A controlled study on the effect of beta-glucan-rich oat bran on serum lipids in hypercholesterolemic subjects: relation to apolipoprotein E phenotype.
abstract: The effects of beta-glucan-rich oat bran on serum lipids and lipoproteins were examined in a randomized 8-week study. After a 4-week run-in phase, subjects with mild to moderate hypercholesterolemia [serum total cholesterol (TC) 5.5-8.5 mmol/l] on cholesterol-lowering diets were randomly allocated to an oat bran (10.3 g beta-glucan/day) or wheat bran group. Thirty-six subjects (20 in the oat bran group, 16 in the wheat bran group) completed the study. The diet was identical in both groups during the trial and no significant changes in body weight were found. Serum TC and low-density lipoprotein cholesterol (LDL-C) significantly declined in the oat bran group during the first 4 weeks from 7.03 +/- 0.81 to 6.72 +/- 0.97 (p = 0.028) and from 4.90 +/- 0.69 to 4.61 +/- 0.89 mmol/l (p = 0.038), respectively, but at 8 weeks the values were not significantly different from baseline. Changes in serum TC were mainly confined to those who ate at least two-thirds of the planned daily dose of oat bran. In wheat bran group no changes were observed in serum TC or LDL-C levels. Apolipoprotein A1 and B did not change significantly in either group. Only subjects with apolipoprotein E 3/3 phenotype (n = 12) had hypocholesterolemic response to oat bran at 4 weeks, but no change was found in those with apolipoprotein E 4/4 or 4/3 (n = 7).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Clinical Nutrition, University of Kuopio, Finland.
authors.forename: M I
authors.initials: MI
authors.lastname: Uusitupa
authors.forename: E
authors.initials: E
authors.lastname: Ruuskanen
authors.forename: E
authors.initials: E
authors.lastname: Mäkinen
authors.forename: J
authors.initials: J
authors.lastname: Laitinen
authors.forename: E
authors.initials: E
authors.lastname: Toskala
authors.forename: K
authors.initials: K
authors.lastname: Kervinen
authors.forename: Y A
authors.initials: YA
authors.lastname: Kesäniemi
mesh_terms: D000328:Adult; D001057:Apolipoproteins E / Q000097:blood*; D001786:Blood Glucose / Q000378:metabolism; D015992:Body Mass Index; D002784:Cholesterol / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D004032:Diet; D004043:Dietary Fiber / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002523:Edible Grain; D005260:Female; D005936:Glucans / Q000008:administration & dosage*; D006801:Humans; D006937:Hypercholesterolemia / Q000178:diet therapy*; D007328:Insulin / Q000097:blood; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010641:Phenotype
chemical_list: D001057:Apolipoproteins E; D001786:Blood Glucose; D008078:Cholesterol, LDL; D004043:Dietary Fiber; D005936:Glucans; D007328:Insulin; D008055:Lipids; D002784:Cholesterol